A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors

Key Eligibility Criteria :

1. Participants must sign a written informed consent form (ICF); and agree to complywith study requirement

2. Phase 1a (Dose Escalation): Part A, A-CN, and B: Participants with histologically or cytologically confirmedunresectable locally advanced or metastatic solid tumor previously treated withstandard systemic therapy or for whom treatment is not available or not toleratedNote: Only Chinese participants will be eligible for Part A-CN. Part C: Participant has histologically or cytologically confirmed, locally advanced,unresectable Stage III Non-small cell lung cancer (NSCLC) suitable for definitivechemoradiotherapy (CRT) Part D: Participant with locally advanced, histologically confirmed inoperableesophageal squamous cell carcinoma (ESCC) suitable for definitive CRT Phase 1b (Dose Expansion): Participants with histologically or cytologicallyconfirmed solid tumors of selected types previously treated with standard therapy.

3. Participants must be able to provide formalin-fixed paraffin embedded (FFPE) tumortissue sample.

4. Phase 1a Part A, A-CN, B and Phase 1b: ≥ 1 measurable lesion per Response evaluationcriteria in solid tumors (RECIST) v1.1

5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1

Key Exclusion Criteria:

1. Active leptomeningeal disease or uncontrolled, untreated brain metastasis.

2. Any malignancy ≤ 3 years before the first dose of study drug(s) except for thespecific cancer under investigation in this study and any locally recurring cancerthat has been treated with curative intent

3. Any condition that required systemic treatment with either corticosteroids or otherimmunosuppressive medication ≤ 14 days before the first dose of study drug(s).

4. Clinically significant infection requiring systemic therapy ≤ 14 days before thefirst dose of study drug(s).

5. Prior exposure to agents with second mitochondria-derived activator of caspases (SMAC) mimetics, or other Inhibitors of apoptosis proteins (IAPs) antagonists.

NOTE: Other protocol defined inclusion/exclusion criteria may apply.